News headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.7046653803178 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Aerie Pharmaceuticals (NASDAQ AERI) traded down $0.05 during mid-day trading on Friday, reaching $53.50. 12,112 shares of the company’s stock were exchanged, compared to its average volume of 377,256. Aerie Pharmaceuticals has a twelve month low of $38.14 and a twelve month high of $66.60. The stock has a market capitalization of $2,088.23, a PE ratio of -16.00 and a beta of 0.87. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Wednesday, November 8th. The company reported ($0.89) EPS for the quarter. sell-side analysts predict that Aerie Pharmaceuticals will post -3.97 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/02/09/aerie-pharmaceuticals-aeri-earns-coverage-optimism-score-of-0-08.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.